LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Glucose Monitoring Devices Market to Reach USD 2 Billion in 2022

By LabMedica International staff writers
Posted on 04 Apr 2018
The global POC blood glucose monitoring devices market is expected to reach USD 2.03 billion in 2022, driven mainly by public and private initiatives to reduce diabetic cases. However, the high cost associated with diabetes management is one of the major factors hindering the market growth.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Most POC blood glucose monitoring devices manufactured by global and local players are cost-efficient. However, the cost associated with diabetes management in high, resulting in out-of-pocket expenditure for consumables used in POC blood glucose monitoring devices. These consumables, including blood glucose test strips, reagents, and cassettes are expensive and are required on a daily basis. Moreover, an invasive device such as lancet needs to be purchased separately along with the POC blood monitoring devices, resulting in additional cost being incurred.

Of late, there has been a paradigm shift to non-invasive products in the POC blood glucose monitoring devices market. Non-invasive POC blood glucose monitoring devices are hand-held units that offer a number of benefits over finger prick glucose test, such as helping to avoid finger prick and providing a convenient, easy to read large number display. Non-invasive POC blood glucose monitoring devices can also track patient compliance and allow multiple tests to be run in order to allow healthcare providers to provide adequate therapeutic decisions.

Related Links:
Research and Markets

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Immunochromatographic Assay
CRYPTO Cassette

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more